The oncology therapy developer has filed for an IPO just two years after emerging from stealth to advance Harvard and Stanford research.
Century Therapeutics, a US-based cancer treatment developer exploiting research at Harvard and Stanford universities, has filed for an initial public offering on the Nasdaq Global Select Market.
The company has not yet set any financial terms and used a $100m placeholder amount.
Founded in 2018 and incubated by venture capital firm Versant Ventures, Century has built an allogeneic cell therapy platform to support the development of cancer immunotherapies. Its lead drug candidate, CNTY-101, is being developed to treat lymphoma, a type of cancer that develops in the immune system.
The IPO proceeds will fund an investigational new drug application for CNTY-101 and preclinical activities ahead of a planned phase 1 trial. It will also fund research and development as well as the development of manufacturing facilities.
Investment firm Casdin Capital led Century’s $160m series C round in March 2021, with participation from chemical and pharmaceutical group Bayer’s corporate…
